D 7991

Drug Profile

D 7991

Latest Information Update: 06 Oct 1997

Price : $50

At a glance

  • Originator Celltech Group
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chemotherapy-induced damage

Most Recent Events

  • 06 Oct 1997 Discontinued-II for Chemotherapy induced damage (Prevention) in United Kingdom (IV)
  • 13 Jan 1997 Phase-II clinical trials for Chemotherapy induced damage (Prevention)/Chemoprotection in United Kingdom (IV)
  • 22 Jul 1996 Investigation in Chemotherapy induced damage (Prevention)/Chemoprotection in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top